Updates the February 11 slide deck. Includes data on the immune response to SARS-CoV-2, efficacy data for the Oxford-AstraZeneca vaccine, and updates the vaccine recommendations from the Canadian Network of MS Clinics.
13 slides
Latest News
COVID-19 vaccines and Multiple sclerosis
February 11, 2021Includes the SARS-CoV-2 life cycle, vaccine targets, COVID-19 vaccines in use and in late-stage development, mRNA vaccine phase III data, and the Canadian Network of MS Clinics’ vaccine guidance.
19 slides
Novel anti-CD20 monoclonal approved in Canada for MS
January 27, 2021Ofatumumab (Kesimpta), a new anti-CD20 monoclonal antibody, has received approval from Health Canada for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with active disease defined by clinical and imaging features. In clinical trials, active disease was defined as at least one relapse or one Gd-enhancing lesion in the previous year.
Slide deck: COVID-19 – Epidemiology in Canada (January 25, 2021)
January 25, 2021Summary of epidemiology, testing and mortality rate; Canada and world statistics.